| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
|
Medicine details |
|
| Medicine name | aripiprazole (Abilify®) |
| Formulation | 5 mg, 10 mg, 15 mg, 30 mg tablet; 10 mg, 15 mg orodispersible tablet; 1 mg/ml oral solution |
| Reference number | 721 |
| Indication | Treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older |
| Company | Otsuka Pharmaceutical (UK) Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/05/2013 |
| NICE guidance | |